Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

Christian Manzardo; Maria C. Londoño; LLuís Castells; Milagros Testillano; José Luis Montero; Judit Peñafiel; Marta Subirana; Ana Moreno; Victoria Aguilera; María Luisa González-Diéguez; Jorge Calvo-Pulido; Xavier Xiol; Magdalena Salcedo; Valentin Cuervas-Mons; José Manuel Sousa; Francisco Suarez; Trinidad Serrano; Jose Ignacio Herrero; Miguel Jiménez; José R. Fernandez; Carlos Giménez; Santos del Campo; Juan I. Esteban-Mur; Gonzalo Crespo; Asunción Moreno; Gloria de la Rosa; Antoni Rimola; Jose M. Miro; F. Suárez; M. A. Castro; S. López; J. D. Pedreira; P. Vázquez; F. Agüero; J. Blanch; M. Brunet; D. Calatayud; C. Cervera; E. de Lazzari; C. Fondevila; A. Forner; J. Fuster; X. Forns; A. Gil; J. M. Gatell; M. Laguno; A. Lligoña; J. Mallolas; J. Murillas; M. Navasa; D. Paredes; I. Pérez; F. Torres; C. Tural; M. Tuset; A. Antela; E. Losada; E. Molina; E. Otero; E. Varo; J. J. Araiz; E. Barrao; J. Larraga; S. Letona; R. Lozano; P. Luque; A. Navarro; I. Sanjoaquín; E. Tejero; R. Bañares; J. Berenguer; G. Clemente; J. Cosín; J. P. Ferreiroa; J. L. García-Sabrido; I. Gutiérrez; J. C. López; P. Miralles; M. Ramírez; D. Rincón; M. Sánchez; J. de la Cruz; J. L. Fernández; J. M. Lozano; J. Santoyo; J. M. Rodrigo; M. A. Suárez; M. Rodríguez; M. P. Alonso; V. Asensi; I. González-Pinto; A. Rafecas; C. Baliellas; J. Carratalá; J. Fabregat; N. Fernández; R. Jorba; L. Lladó; M. Montejo; J. Bustamante

doi:10.1111/ajt.14996

Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

Christian Manzardo, Maria C. Londoño, LLuís Castells, Milagros Testillano, José Luis Montero, Judit Peñafiel, Marta Subirana, Ana Moreno, Victoria Aguilera, María Luisa González-Diéguez, Jorge Calvo-Pulido, Xavier Xiol, Magdalena Salcedo, Valentin Cuervas-Mons, José Manuel Sousa, Francisco Suarez, Trinidad Serrano, Jose Ignacio Herrero, Miguel Jiménez, José R. FernandezCarlos Giménez, Santos del Campo, Juan I. Esteban-Mur, Gonzalo Crespo, Asunción Moreno, Gloria de la Rosa, Antoni Rimola, Jose M. Miro, F. Suárez, M. A. Castro, S. López, J. D. Pedreira, P. Vázquez, F. Agüero, J. Blanch, M. Brunet, D. Calatayud, C. Cervera, E. de Lazzari, C. Fondevila, A. Forner, J. Fuster, X. Forns, A. Gil, J. M. Gatell, M. Laguno, A. Lligoña, J. Mallolas, J. Murillas, M. Navasa, D. Paredes, I. Pérez, F. Torres, C. Tural, M. Tuset, A. Antela, E. Losada, E. Molina, E. Otero, E. Varo, J. J. Araiz, E. Barrao, J. Larraga, S. Letona, R. Lozano, P. Luque, A. Navarro, I. Sanjoaquín, E. Tejero, R. Bañares, J. Berenguer, G. Clemente, J. Cosín, J. P. Ferreiroa, J. L. García-Sabrido, I. Gutiérrez, J. C. López, P. Miralles, M. Ramírez, D. Rincón, M. Sánchez, J. de la Cruz, J. L. Fernández, J. M. Lozano, J. Santoyo, J. M. Rodrigo, M. A. Suárez, M. Rodríguez, M. P. Alonso, V. Asensi, I. González-Pinto, A. Rafecas, C. Baliellas, J. Carratalá, J. Fabregat, N. Fernández, R. Jorba, L. Lladó, M. Montejo, J. Bustamante

Research output: Contribution to journal › Article › Research

25 Citations (Scopus)

Abstract

© 2018 The American Society of Transplantation and the American Society of Transplant Surgeons Direct-acting antivirals have proved to be highly efficacious and safe in monoinfected liver transplant (LT) recipients who experience recurrence of hepatitis C virus (HCV) infection. However, there is a lack of data on effectiveness and tolerability of these regimens in HCV/HIV-coinfected patients who experience recurrence of HCV infection after LT. In this prospective, multicenter cohort study, the outcomes of 47 HCV/HIV-coinfected LT patients who received DAA therapy (with or without ribavirin [RBV]) were compared with those of a matched cohort of 148 HCV-monoinfected LT recipients who received similar treatment. Baseline characteristics were similar in both groups. HCV/HIV-coinfected patients had a median (IQR) CD4 T-cell count of 366 (256-467) cells/µL. HIV-RNA was <50 copies/mL in 96% of patients. The DAA regimens administered were SOF + LDV ± RBV (34%), SOF + SMV ± RBV (31%), SOF + DCV ± RBV (27%), SMV + DCV ± RBV (5%), and 3D (3%), with no differences between the groups. Treatment was well tolerated in both groups. Rates of SVR (negative serum HCV-RNA at 12 weeks after the end of treatment) were high and similar for coinfected and monoinfected patients (95% and 94%, respectively; P =.239). Albeit not significant, a trend toward lower SVR rates among patients with advanced fibrosis (P =.093) and genotype 4 (P =.088) was observed. In conclusion, interferon-free regimens with DAAs for post-LT recurrence of HCV infection in HIV-infected individuals were highly effective and well tolerated, with results comparable to those of HCV-monoinfected patients.

Original language	English
Pages (from-to)	2513-2522
Journal	American Journal of Transplantation
Volume	18
DOIs	https://doi.org/10.1111/ajt.14996
Publication status	Published - 1 Oct 2018

Keywords

clinical research/practice
infection and infectious agents—viral: hepatitis C
infection and infectious agents—viral: human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)
liver transplantation/hepatology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/ajt.14996

Cite this

Manzardo, C., Londoño, M. C., Castells, LL., Testillano, M., Luis Montero, J., Peñafiel, J., Subirana, M., Moreno, A., Aguilera, V., Luisa González-Diéguez, M., Calvo-Pulido, J., Xiol, X., Salcedo, M., Cuervas-Mons, V., Manuel Sousa, J., Suarez, F., Serrano, T., Ignacio Herrero, J., Jiménez, M., ... Bustamante, J. (2018). Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study. American Journal of Transplantation, 18, 2513-2522. https://doi.org/10.1111/ajt.14996

@article{5ec1042328554a928c57f187f51147e4,

title = "Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study",

abstract = "{\textcopyright} 2018 The American Society of Transplantation and the American Society of Transplant Surgeons Direct-acting antivirals have proved to be highly efficacious and safe in monoinfected liver transplant (LT) recipients who experience recurrence of hepatitis C virus (HCV) infection. However, there is a lack of data on effectiveness and tolerability of these regimens in HCV/HIV-coinfected patients who experience recurrence of HCV infection after LT. In this prospective, multicenter cohort study, the outcomes of 47 HCV/HIV-coinfected LT patients who received DAA therapy (with or without ribavirin [RBV]) were compared with those of a matched cohort of 148 HCV-monoinfected LT recipients who received similar treatment. Baseline characteristics were similar in both groups. HCV/HIV-coinfected patients had a median (IQR) CD4 T-cell count of 366 (256-467) cells/µL. HIV-RNA was <50 copies/mL in 96% of patients. The DAA regimens administered were SOF + LDV ± RBV (34%), SOF + SMV ± RBV (31%), SOF + DCV ± RBV (27%), SMV + DCV ± RBV (5%), and 3D (3%), with no differences between the groups. Treatment was well tolerated in both groups. Rates of SVR (negative serum HCV-RNA at 12 weeks after the end of treatment) were high and similar for coinfected and monoinfected patients (95% and 94%, respectively; P =.239). Albeit not significant, a trend toward lower SVR rates among patients with advanced fibrosis (P =.093) and genotype 4 (P =.088) was observed. In conclusion, interferon-free regimens with DAAs for post-LT recurrence of HCV infection in HIV-infected individuals were highly effective and well tolerated, with results comparable to those of HCV-monoinfected patients.",

keywords = "clinical research/practice, infection and infectious agents—viral: hepatitis C, infection and infectious agents—viral: human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), liver transplantation/hepatology",

author = "Christian Manzardo and Londo{\~n}o, {Maria C.} and LLu{\'i}s Castells and Milagros Testillano and {Luis Montero}, Jos{\'e} and Judit Pe{\~n}afiel and Marta Subirana and Ana Moreno and Victoria Aguilera and {Luisa Gonz{\'a}lez-Di{\'e}guez}, Mar{\'i}a and Jorge Calvo-Pulido and Xavier Xiol and Magdalena Salcedo and Valentin Cuervas-Mons and {Manuel Sousa}, Jos{\'e} and Francisco Suarez and Trinidad Serrano and {Ignacio Herrero}, Jose and Miguel Jim{\'e}nez and Fernandez, {Jos{\'e} R.} and Carlos Gim{\'e}nez and {del Campo}, Santos and Esteban-Mur, {Juan I.} and Gonzalo Crespo and Asunci{\'o}n Moreno and {de la Rosa}, Gloria and Antoni Rimola and Miro, {Jose M.} and F. Su{\'a}rez and Castro, {M. A.} and S. L{\'o}pez and Pedreira, {J. D.} and P. V{\'a}zquez and F. Ag{\"u}ero and J. Blanch and M. Brunet and D. Calatayud and C. Cervera and {de Lazzari}, E. and C. Fondevila and A. Forner and J. Fuster and X. Forns and A. Gil and Gatell, {J. M.} and M. Laguno and A. Lligo{\~n}a and J. Mallolas and J. Murillas and M. Navasa and D. Paredes and I. P{\'e}rez and F. Torres and C. Tural and M. Tuset and A. Antela and E. Losada and E. Molina and E. Otero and E. Varo and Araiz, {J. J.} and E. Barrao and J. Larraga and S. Letona and R. Lozano and P. Luque and A. Navarro and I. Sanjoaqu{\'i}n and E. Tejero and R. Ba{\~n}ares and J. Berenguer and G. Clemente and J. Cos{\'i}n and Ferreiroa, {J. P.} and Garc{\'i}a-Sabrido, {J. L.} and I. Guti{\'e}rrez and L{\'o}pez, {J. C.} and P. Miralles and M. Ram{\'i}rez and D. Rinc{\'o}n and M. S{\'a}nchez and {de la Cruz}, J. and Fern{\'a}ndez, {J. L.} and Lozano, {J. M.} and J. Santoyo and Rodrigo, {J. M.} and Su{\'a}rez, {M. A.} and M. Rodr{\'i}guez and Alonso, {M. P.} and V. Asensi and I. Gonz{\'a}lez-Pinto and A. Rafecas and C. Baliellas and J. Carratal{\'a} and J. Fabregat and N. Fern{\'a}ndez and R. Jorba and L. Llad{\'o} and M. Montejo and J. Bustamante",

year = "2018",

month = oct,

day = "1",

doi = "10.1111/ajt.14996",

language = "English",

volume = "18",

pages = "2513--2522",

}

Manzardo, C, Londoño, MC, Castells, LL, Testillano, M, Luis Montero, J, Peñafiel, J, Subirana, M, Moreno, A, Aguilera, V, Luisa González-Diéguez, M, Calvo-Pulido, J, Xiol, X, Salcedo, M, Cuervas-Mons, V, Manuel Sousa, J, Suarez, F, Serrano, T, Ignacio Herrero, J, Jiménez, M, Fernandez, JR, Giménez, C, del Campo, S, Esteban-Mur, JI, Crespo, G, Moreno, A, de la Rosa, G, Rimola, A, Miro, JM, Suárez, F, Castro, MA, López, S, Pedreira, JD, Vázquez, P, Agüero, F, Blanch, J, Brunet, M, Calatayud, D, Cervera, C, de Lazzari, E, Fondevila, C, Forner, A, Fuster, J, Forns, X, Gil, A, Gatell, JM, Laguno, M, Lligoña, A, Mallolas, J, Murillas, J, Navasa, M, Paredes, D, Pérez, I, Torres, F , Tural, C, Tuset, M, Antela, A, Losada, E, Molina, E, Otero, E, Varo, E, Araiz, JJ, Barrao, E, Larraga, J, Letona, S, Lozano, R, Luque, P, Navarro, A, Sanjoaquín, I, Tejero, E, Bañares, R, Berenguer, J, Clemente, G, Cosín, J, Ferreiroa, JP, García-Sabrido, JL, Gutiérrez, I, López, JC, Miralles, P, Ramírez, M, Rincón, D, Sánchez, M, de la Cruz, J, Fernández, JL, Lozano, JM, Santoyo, J, Rodrigo, JM, Suárez, MA, Rodríguez, M, Alonso, MP, Asensi, V, González-Pinto, I, Rafecas, A, Baliellas, C, Carratalá, J, Fabregat, J, Fernández, N, Jorba, R, Lladó, L, Montejo, M & Bustamante, J 2018, 'Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study', American Journal of Transplantation, vol. 18, pp. 2513-2522. https://doi.org/10.1111/ajt.14996

Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study. / Manzardo, Christian; Londoño, Maria C.; Castells, LLuís et al.

In: American Journal of Transplantation, Vol. 18, 01.10.2018, p. 2513-2522.

Research output: Contribution to journal › Article › Research

TY - JOUR

T1 - Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

AU - Manzardo, Christian

AU - Londoño, Maria C.

AU - Castells, LLuís

AU - Testillano, Milagros

AU - Luis Montero, José

AU - Peñafiel, Judit

AU - Subirana, Marta

AU - Moreno, Ana

AU - Aguilera, Victoria

AU - Luisa González-Diéguez, María

AU - Calvo-Pulido, Jorge

AU - Xiol, Xavier

AU - Salcedo, Magdalena

AU - Cuervas-Mons, Valentin

AU - Manuel Sousa, José

AU - Suarez, Francisco

AU - Serrano, Trinidad

AU - Ignacio Herrero, Jose

AU - Jiménez, Miguel

AU - Fernandez, José R.

AU - Giménez, Carlos

AU - del Campo, Santos

AU - Esteban-Mur, Juan I.

AU - Crespo, Gonzalo

AU - Moreno, Asunción

AU - de la Rosa, Gloria

AU - Rimola, Antoni

AU - Miro, Jose M.

AU - Suárez, F.

AU - Castro, M. A.

AU - López, S.

AU - Pedreira, J. D.

AU - Vázquez, P.

AU - Agüero, F.

AU - Blanch, J.

AU - Brunet, M.

AU - Calatayud, D.

AU - Cervera, C.

AU - de Lazzari, E.

AU - Fondevila, C.

AU - Forner, A.

AU - Fuster, J.

AU - Forns, X.

AU - Gil, A.

AU - Gatell, J. M.

AU - Laguno, M.

AU - Lligoña, A.

AU - Mallolas, J.

AU - Murillas, J.

AU - Navasa, M.

AU - Paredes, D.

AU - Pérez, I.

AU - Torres, F.

AU - Tural, C.

AU - Tuset, M.

AU - Antela, A.

AU - Losada, E.

AU - Molina, E.

AU - Otero, E.

AU - Varo, E.

AU - Araiz, J. J.

AU - Barrao, E.

AU - Larraga, J.

AU - Letona, S.

AU - Lozano, R.

AU - Luque, P.

AU - Navarro, A.

AU - Sanjoaquín, I.

AU - Tejero, E.

AU - Bañares, R.

AU - Berenguer, J.

AU - Clemente, G.

AU - Cosín, J.

AU - Ferreiroa, J. P.

AU - García-Sabrido, J. L.

AU - Gutiérrez, I.

AU - López, J. C.

AU - Miralles, P.

AU - Ramírez, M.

AU - Rincón, D.

AU - Sánchez, M.

AU - de la Cruz, J.

AU - Fernández, J. L.

AU - Lozano, J. M.

AU - Santoyo, J.

AU - Rodrigo, J. M.

AU - Suárez, M. A.

AU - Rodríguez, M.

AU - Alonso, M. P.

AU - Asensi, V.

AU - González-Pinto, I.

AU - Rafecas, A.

AU - Baliellas, C.

AU - Carratalá, J.

AU - Fabregat, J.

AU - Fernández, N.

AU - Jorba, R.

AU - Lladó, L.

AU - Montejo, M.

AU - Bustamante, J.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - © 2018 The American Society of Transplantation and the American Society of Transplant Surgeons Direct-acting antivirals have proved to be highly efficacious and safe in monoinfected liver transplant (LT) recipients who experience recurrence of hepatitis C virus (HCV) infection. However, there is a lack of data on effectiveness and tolerability of these regimens in HCV/HIV-coinfected patients who experience recurrence of HCV infection after LT. In this prospective, multicenter cohort study, the outcomes of 47 HCV/HIV-coinfected LT patients who received DAA therapy (with or without ribavirin [RBV]) were compared with those of a matched cohort of 148 HCV-monoinfected LT recipients who received similar treatment. Baseline characteristics were similar in both groups. HCV/HIV-coinfected patients had a median (IQR) CD4 T-cell count of 366 (256-467) cells/µL. HIV-RNA was <50 copies/mL in 96% of patients. The DAA regimens administered were SOF + LDV ± RBV (34%), SOF + SMV ± RBV (31%), SOF + DCV ± RBV (27%), SMV + DCV ± RBV (5%), and 3D (3%), with no differences between the groups. Treatment was well tolerated in both groups. Rates of SVR (negative serum HCV-RNA at 12 weeks after the end of treatment) were high and similar for coinfected and monoinfected patients (95% and 94%, respectively; P =.239). Albeit not significant, a trend toward lower SVR rates among patients with advanced fibrosis (P =.093) and genotype 4 (P =.088) was observed. In conclusion, interferon-free regimens with DAAs for post-LT recurrence of HCV infection in HIV-infected individuals were highly effective and well tolerated, with results comparable to those of HCV-monoinfected patients.

AB - © 2018 The American Society of Transplantation and the American Society of Transplant Surgeons Direct-acting antivirals have proved to be highly efficacious and safe in monoinfected liver transplant (LT) recipients who experience recurrence of hepatitis C virus (HCV) infection. However, there is a lack of data on effectiveness and tolerability of these regimens in HCV/HIV-coinfected patients who experience recurrence of HCV infection after LT. In this prospective, multicenter cohort study, the outcomes of 47 HCV/HIV-coinfected LT patients who received DAA therapy (with or without ribavirin [RBV]) were compared with those of a matched cohort of 148 HCV-monoinfected LT recipients who received similar treatment. Baseline characteristics were similar in both groups. HCV/HIV-coinfected patients had a median (IQR) CD4 T-cell count of 366 (256-467) cells/µL. HIV-RNA was <50 copies/mL in 96% of patients. The DAA regimens administered were SOF + LDV ± RBV (34%), SOF + SMV ± RBV (31%), SOF + DCV ± RBV (27%), SMV + DCV ± RBV (5%), and 3D (3%), with no differences between the groups. Treatment was well tolerated in both groups. Rates of SVR (negative serum HCV-RNA at 12 weeks after the end of treatment) were high and similar for coinfected and monoinfected patients (95% and 94%, respectively; P =.239). Albeit not significant, a trend toward lower SVR rates among patients with advanced fibrosis (P =.093) and genotype 4 (P =.088) was observed. In conclusion, interferon-free regimens with DAAs for post-LT recurrence of HCV infection in HIV-infected individuals were highly effective and well tolerated, with results comparable to those of HCV-monoinfected patients.

KW - clinical research/practice

KW - infection and infectious agents—viral: hepatitis C

KW - infection and infectious agents—viral: human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)

KW - liver transplantation/hepatology

U2 - 10.1111/ajt.14996

DO - 10.1111/ajt.14996

M3 - Article

C2 - 29963780

VL - 18

SP - 2513

EP - 2522

ER -

Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this